NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Scopus
BioPharma Inc. (Nasdaq: SCPS) today announced the closing of
the underwriters' over-allotment option in full, bringing total
follow-on public offering proceeds to $10.35
million.
Scopus is a biopharmaceutical company developing
transformational therapeutics based on groundbreaking scientific
and medical discoveries. The company's lead drug candidate is
a novel, targeted immuno-oncology gene therapy for the treatment of
multiple cancers.
Scopus intends to use the total proceeds of the follow-on public
offering, including the proceeds from the exercise of the
over-allotment option, principally for further development of the
company's lead drug candidate, including in combination with
checkpoint inhibitors.
The Benchmark Company, LLC acted as Sole Bookrunning Manager and
Joseph Gunnar & Co., LLC acted
as Co-Manager for the offering.
Greenberg Traurig, LLP is acting as counsel to the
company. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
is acting as counsel to the underwriters.
An offering statement relating to the shares of common stock was
filed with the U.S. Securities and Exchange Commission and became
qualified on January 26, 2021. The
offering is being made only by means of an offering circular,
copies of which may be obtained, when available, by contacting: The
Benchmark Company, LLC, Attention: Prospectus Department, 150 E.
58th Street, 17th Floor, New York,
NY 10155, by calling (212) 312-6700 or by e-mail at
prospectus@benchmarkcompany.com; or Joseph
Gunnar & Co., LLC, Attention: Prospectus Department, 30
Broad Street, 11th Floor, New York,
NY 10004, by calling (212) 440-9600 or by email at
prospectus@jgunnar.com. The offering circular is also
available on the U.S. Securities and Exchange Commission website at
www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any
such state or jurisdiction.
About Scopus BioPharma
Scopus BioPharma Inc. is a biopharmaceutical company developing
transformational therapeutics capitalizing on groundbreaking
scientific and medical discoveries from leading research and
academic institutions. The company's lead drug candidate is a
novel, targeted immuno-oncology gene therapy for the treatment of
multiple cancers. This drug candidate is highly distinctive,
encompassing both gene therapy and immunotherapy by synthetically
linking siRNA to an oligonucleotide TLR9 agonist, creating the
potential for targeted gene silencing with simultaneous TLR
stimulation and immune activation in the tumor
microenvironment. The company is also developing additional
new chemical entities to treat other serious diseases with
significant unmet medical needs, including systemic sclerosis.
Forward-Looking Statements
This press release may include forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements are subject to risks (including those set forth in the
company's offering circular filed with the U.S. Securities and
Exchange Commission) and uncertainties which could cause actual
results to differ from the forward-looking statements. The company
expressly disclaims any obligations or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the company's
expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Investors should realize that if our underlying assumptions for the
projections contained herein prove inaccurate or that known or
unknown risks or uncertainties materialize, actual results could
vary materially from our expectations and projections.
Contact
Rodd Leeds/David Waldman
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: SCPS@crescendo-ir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/scopus-biopharma-announces-closing-of-underwriters-over-allotment-option-in-full-301226474.html
SOURCE Scopus BioPharma Inc.